Andrew Coveler, MD
Medical Oncology · Seattle, WANPI 1669535670
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Taiho Oncology, Inc. accounts for 70.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $9,490 and has fallen 67.7% since, to $3,066 in 2025.
Across 24 payments — averaging $524.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Taiho Oncology, Inc.$9K
- Ipsen Biopharmaceuticals, Inc$2K
- Kyowa Kirin Co., Ltd$1K
- Seagen Inc.$27
Across 535 payments — averaging $13,292 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.6M
- AstraZeneca$1.2M
- Seagen Inc.$1.2M
- Astrazeneca UK Limited$1M
- Mirati Therapeutics, Inc.$479K
- Daiichi Sankyo Inc.$194K
- plus $378K from 6 others
What the payments were for
- Consulting fees$1,56012%
- Speaking & faculty fees$6,37551%
- Travel & lodging$3,53228%
- Food & beverage$1,1179%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Taiho Oncology, Inc. | 12 | $8,874 |
| Ipsen Biopharmaceuticals, Inc | 2 | $2,340 |
| Kyowa Kirin Co., Ltd | 9 | $1,342 |
| Seagen Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,584 in reported general payments places this provider in the 70th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 56 | $140,322 |
| Prochlorperazine Maleate | 46 | $950 |
| LoperamideLoperamide Hcl | 37 | $511 |
| Ondansetron Hcl | 40 | $403 |
| Oxycodone Hcl | 27 | $393 |
| Olanzapine | 15 | $381 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 25 | $284 |
| Famotidine | 17 | $222 |
| Dexamethasone | 15 | $162 |
| Potassium Chloride | 13 | $83 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.